Modern therapy for patients with combined liver and cardiovascular diseases
https://doi.org/10.51793/OS.2026.29.1.006
Abstract
Background. In December 2025, a hybrid (in-person and online) Scientific-Practical Conference "Moscow Gastroenterological Council. Year's Results" was held in Moscow. At the event, leading gastroenterology specialists gathered to discuss current issues in the treatment of hepatobiliary system diseases and to share experiences.
Results. The conference was an important event for practicing physicians, allowing them to stay abreast of the latest trends in medicine. The most pressing issues in modern gastroenterology were discussed – inflammatory bowel diseases, comorbid pathology, and interdisciplinary aspects. The symposium "Interdisciplinary Tasks in Hepatology. Practical Solutions," held as part of the conference, focused on effective approaches to therapy for patients with combined pathology (non-alcoholic fatty liver disease + cardiovascular diseases), as well as new clinical guidelines for drug-induced liver injury. The symposium's presidium included M. V. Maevskaya, Cand. of Sci. (Med.), Professor, Consultant of Medical and Diagnostic Department No. 3 of the University Clinical Hospital No. 2, I. M. Sechenov First Moscow State Medical University (Sechenov University) Ministry of Health of the Russian Federation, Vice-President of the Russian Society for Liver Research, Moscow, Russia, and E. V. Vinnitskaya, Dr. of Sci. (Med.), Chief Researcher of the Hepatology Department at the A. S. Loginov Moscow Clinical Research Center.
About the Author
M. V. Chirkova
The Lechaschi Vrach journal
Россия
Россия
Marina V. Chirkova, editor
a/z 82 Moscow, 123056
References
1. Belenichev I., et al. Possibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia. Pharmaceuticals (Basel). 2025; 18 (1): 106. DOI: 10.3390/ph18010106.
2. Popazova O., et al. Cardioprotective Activity of Pharmacological Agents Affecting NO Production and Bioavailability in the Early Postnatal Period after Intrauterine Hypoxia in Rats. Biomedicines. 2023; 11 (10): 2854. DOI: 10.3390/biomedicines11102854.
3. Prikhodko V. A., Okovity S. V. Possibilities of using morpholinium thiazotate as a means of pharmacotherapy for conditions of the hepatocardial continuum. Meditsinskii Sovet. 2024; 18 (23): 94-103. https://doi.org/10.21518/ms2024-517. (In Russ.)
4. Kadin D. V., Chumak B. A., Filippov A. E., Shustov S. B. Thiotriazoline in complex therapy of stable angina pectoris of functional class II-III. Kardiologiia. 2015. 55 (8): 26-29. DOI: 10.18565/cardio.2015.8.26-29. (In Russ.)
5. Lazebnik L. B., Golovanova E. V., Simanenkov V. I., Grinevich V. B., Uspensky Y. P., Bakulin I. G., Bakulina N. V., Lutayenko E. A., Kravchuk Y. A., Bakulova E. V. Possibilities of polytropic therapy with thiotriazoline in patients with non-alcoholic steatohepatitis and cardiovascular risk factors. Results of the observational program "TRIGON-1". Eksperimental'naya i Klinicheskaya Gastroenterologiya. 2020; 8: 10-18. DOI: 10.31146/1682-8658-ecg-180-8-10-18. (In Russ.)
6. Tagher G., et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016; 65 (3): 589-600. DOI:10.1016/j.jhep.2016.05.013.
7. Quek J., et al. Metabolic Associated Fatty Liver Disease Increases the Risk of Cystemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals. Endocr Pract. 2022; 28 (7): 667-672. https://doi.org/10.1016/j.eprac.2022.03.016.
8. Polukhina A. V., Vinnitskaya E. V., Bordin D. S., Sandler Yu. G. Non-alcoholic fatty liver disease in comorbid patients: experience of therapy with Thiotriazoline. Effektivnaya Farmakoterapiya. 2018; 3 (32): 20-24. (In Russ.)
9. Kol'tsov A. V., Tyrenko V. V. Cardioprotective effect of thiotriazoline in cancer patients. Rossiiskii Kardiologicheskii Zhurnal. 2023; 28 (1): 5304. https://doi.org/10.15829/1560-4071-2023-5304. (In Russ.)
10. Shovkun L. A., Campos E. D., Romantseva N. E. Hepatoprotective and antioxidant effects of thiotriazoline in the treatment of patients with pulmonary tuberculosis. Zhurnal Fundamental'noi Meditsiny i Biologii. 2013; 2: 73-79. (In Russ.)
Review
For citations:
Chirkova M.V. Modern therapy for patients with combined liver and cardiovascular diseases. Lechaschi Vrach. 2026;(1):40-46. (In Russ.) https://doi.org/10.51793/OS.2026.29.1.006
Views:
5
JATS XML
Email this article 
